Can we Reduce the Toxicity of the Mediastinal Irradiation Using New Highly Conformal Techniques?
Victor Pernin, Sofia Zefkili, Dominique Peurien, Alain Fourquet and Youlia M Kirova*
Department of Radiation Oncology, Institute Curie, Paris, France
- *Corresponding Author:
- Youlia M. Kirova
Radiation Oncology, Institute Curie 26
Rue d’Ulm 75005 Paris, France
Tel: 331 44 32 46 37
Fax: 331 44 32 46 16
E-mail: [email protected]
Received date: June 25, 2014; Accepted date: September 02, 2014; Published date: September 10, 2014
Citation: Pernin V, Zefkili S, Peurien D, Fourquet A, Kirova YM (2014) Can we Reduce the Toxicity of the Mediastinal Irradiation Using New Highly Conformal Techniques? J Leuk (Los Angel) 2:154. doi: 10.4172/2329-6917.1000154
Copyright: © 2014 Pernin V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objectives: Three-Dimensional Conformal Radiotherapy (3DCRT) has been successfully used to treat Hodgkin’s Lymphoma (HL) but treatment delivery is often complex and requires large fields that may result in significant exposure of normal tissues to ionizing radiation. The present study was undertaken to compare the dosimetry of Involved Field (IF) 3DCRT to HT in female patients treated for HL. Materials/Methods: A total of 10 young female patients affected with early stage mediastinal HL and treated with IF radiotherapy after chemotherapy were selected from our database. For each patient, 3DCRT and HT plans were designed to deliver 30 Gy to the target volume and 36 Gy in case of residual masses. HT planning solutions were optimized by inverse planning with specific dose-volume constraints on OAR (breasts, lungs, heart). Dose- Volume Histograms (DVHs) were calculated and then compared, both for target and OAR by a statistical analysis (Wilcoxon’s Test).
Results: Mean doses to the PTV were almost identical for all plans. Conformity index was better with HT and homogeneity index didn’t differ. Mean dose to the breasts were increased with HT compared to 33DCRT (right breast: 3.28 vs 2.19, p<0.05; left breast: 3.76 vs 2.81, p<0.05) whereas no difference in mean doses appeared for heart, coronary arteries, lungs, thyroid and normal tissue. Maximal doses were reduced with HT for breasts (right breast: 19.9 vs 28.87, p<0.05; left breast: 24.76 vs 30.29, p<0.05) and spinal cord (20.87 vs 33.88, p<0.05). Volume exposed to high doses was smaller with HT whereas volume exposed to low doses was smaller with 3DCRT. Pronounced benefits of HT in terms of heart sparing were observed for patients with lymph nodes anterior to the heart.
Conclusions: Although high dose to organ at risk was reduced with HT, increasing low dose especially to the breasts must be taken into account for IF HT. HT may be considered for large PTV especially when the anterior mediastinum is involved.